91 related articles for article (PubMed ID: 22220435)
1. Our experiences in treatment of prostate carcinoma in patients over the age of 70.
Maricić A; Valencić M; Sotosek S; Spanjol J; Fuckar Z
Coll Antropol; 2011 Sep; 35 Suppl 2():199-202. PubMed ID: 22220435
[TBL] [Abstract][Full Text] [Related]
2. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
3. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
4. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G; Abdollah F; Schiffmann J; Trudeau V; Shariat SF; Kim SP; Perrotte P; Montorsi F; Briganti A; Trinh QD; Karakiewicz PI; Sun M
Prostate; 2014 Feb; 74(2):210-6. PubMed ID: 24132735
[TBL] [Abstract][Full Text] [Related]
5. [Skip metastasis of prostate cancer: diagnosis and treatment].
Wang JQ; Li W; Wang Q; Liu K; Mao LJ; Chen JC; Zheng JN; Sun XQ
Zhonghua Nan Ke Xue; 2009 Dec; 15(12):1120-3. PubMed ID: 20180426
[TBL] [Abstract][Full Text] [Related]
6. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Koopmans N; de Jong IJ; Breeuwsma AJ; van der Veer E
J Urol; 2007 Sep; 178(3 Pt 1):849-53; discussion 853; quiz 1129. PubMed ID: 17631330
[TBL] [Abstract][Full Text] [Related]
7. [Uncommon initial symptoms of metastasized carcinoma of the prostate].
Wymenga LF; Mensink HJ
Ned Tijdschr Geneeskd; 1999 Oct; 143(42):2081-6. PubMed ID: 10560555
[TBL] [Abstract][Full Text] [Related]
8. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Postma R; Roobol M; Schröder FH; van der Kwast TH
Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
[TBL] [Abstract][Full Text] [Related]
9. Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies.
Maier U; Höbarth K; Simak R
Eur Urol; 1996; 29(2):221-3. PubMed ID: 8647151
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
12. [Progression from adenocarcinoma to small cell carcinoma of the prostate during endocrinotherapy: a case report].
Maeno A; Kamoto T; Kitamura K; Kanno T; Okuno H; Terai A; Kakehi Y; Terachi T; Ogawa O; Matsushiro H
Hinyokika Kiyo; 2001 Aug; 47(8):591-3. PubMed ID: 11579603
[TBL] [Abstract][Full Text] [Related]
13. [Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989-1994].
Visser O; Horenblas S
Ned Tijdschr Geneeskd; 1996 Dec; 140(52):2627-31. PubMed ID: 9026742
[TBL] [Abstract][Full Text] [Related]
14. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
[TBL] [Abstract][Full Text] [Related]
15. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment.
Bantis A; Zissimopoulos A; Kalaitzis C; Giannakopoulos S; Sountoulides P; Parmenopoulou V; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2008; 11(1):21-5. PubMed ID: 18392222
[TBL] [Abstract][Full Text] [Related]
16. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
[TBL] [Abstract][Full Text] [Related]
17. [Small cell carcinoma of the prostate: an autopsy case report].
Shimizu N; Miyatake R; Esa A; Ishikawa Y
Hinyokika Kiyo; 2005 Jun; 51(6):399-402. PubMed ID: 16050480
[TBL] [Abstract][Full Text] [Related]
18. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
19. [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].
Zufferey L; Roques B; Fléchon A; Droz JP
Bull Cancer; 2001 Dec; 88(12):1213-21. PubMed ID: 11792613
[TBL] [Abstract][Full Text] [Related]
20. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
